The estimated Net Worth of Francis E Capitanio is at least $31.7 Thousand dollars as of 27 February 2017. Francis Capitanio owns over 15,000 units of Biomerica stock worth over $31,722 and over the last 11 years Francis sold BMRA stock worth over $0.
Francis has made over 6 trades of the Biomerica stock since 2014, according to the Form 4 filled with the SEC. Most recently Francis exercised 15,000 units of BMRA stock worth $12,300 on 27 February 2017.
The largest trade Francis's ever made was exercising 30,000 units of Biomerica stock on 16 May 2016 worth over $12,000. On average, Francis trades about 11,333 units every 119 days since 2014. As of 27 February 2017 Francis still owns at least 102,000 units of Biomerica stock.
You can see the complete history of Francis Capitanio stock trades at the bottom of the page.
Over the last 12 years, insiders at Biomerica have traded over $80,900 worth of Biomerica stock and bought 151,277 units worth $334,788 . The most active insiders traders include Mark A Sirgo, David Moatazedi, and John P. Kenny. On average, Biomerica executives and independent directors trade stock every 61 days with the average trade being worth of $3,349. The most recent stock trade was executed by Zackary S. Irani on 25 May 2023, trading 700 units of BMRA stock currently worth $1,113.
biomerica, inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. the company’s products are designed to enhance health and well-being, while reducing total healthcare costs. biomerica primarily focuses on products for gastrointestinal disease, diabetes and esoteric testing. the biomerica infoods® ibs product identifies patient specific foods that when removed may alleviate an individual's ibs symptoms. this patent pending diagnostic guided therapy is designed to allow for a patient specific guided dietary regimen to improve irritable bowel syndrome (ibs) outcomes. the point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample while a clinical lab version of the product will be the first for wh
Biomerica executives and other stock owners filed with the SEC include: